Gene Therapies for Rare and Genetic Diseases, 2018 Report - Recent Advances & Clinical Trials - ResearchAndMarkets.com

December 14, 2018

DUBLIN--(BUSINESS WIRE)--Dec 14, 2018--The “Gene Therapies for Rare and Genetic Diseases” report has been added to ResearchAndMarkets.com’s offering.

This edition of the Genetic Technology TOE provides insights across recent developments in gene therapies for rare and genetic disorders. The TOE also provides a clinical trial analysis for ex vivo gene therapy.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions.

The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

Key Topics Covered:

Recent Advances in Gene Therapies that Address Rare and Genetic Diseases

Gene Therapy for Rare Neurological Genetic Diseases Autologous Ex Vivo Gene Therapy for Neurodegenerative Disorders Orphan Drug Accelerators to Improve Rare Diseases Business Model Lentiviral Gene Therapy Solutions for Rare and Genetic Diseases

Clinical Trial Analysis and Key Contacts

Clinical Trial Analysis for Ex Vivo Gene Therapy Key Contacts

For more information about this report visit https://www.researchandmarkets.com/research/r2ljqx/gene_therapies?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181214005523/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Genomics



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/14/2018 03:31 PM/DISC: 12/14/2018 03:31 PM


Update hourly